The Dawn of a New Era: Pharmacogenomic and Food Tolerance Testing Emerges from the Unlikely Alliance of Finance and Healthcare

Screenshot 2023 07 05 at 6.52.24 PM

In a world where the boundaries of industry are increasingly blurred, an unconventional player steps onto the healthcare stage. Amid the steel and glass towers of finance, a new story unfolds as the well-regarded Prince Financial Group ventures into uncharted territory: personalized medicine, navigated with help from Prince Laboratories.

Guiding this unique odyssey is a prince of finance and fresh explorer in the healthcare cosmos – John Engler, co-founder of Prince Financial Group. But he is not alone. Faithfully standing by his side are two other co-founders, Bryan Lantry and Alec Dierna.

Steering the ship, Engler, beside Prince Laboratories Owner and CEO, Thomas Lancie, delve into the intriguing realms of pharmacogenomic testing and food tolerance testing, aiming to weave a new narrative in the vast tapestry of healthcare. “Pharmacogenomic testing reads the encrypted messages in our genes, decrypting the unique ways our bodies react to different medications”, says Lancie.

This groundbreaking strategy allows doctors to tailor treatments to an individual’s genetic script, reducing adverse reactions and amplifying therapeutic outcomes. “It’s akin to a tailored suit, meticulously fitted to every nuance of the body for the perfect fit, enhancing comfort and minimizing discomfort,” he adds.

Parallel to the narrative of pharmacogenomic testing is the subplot of food tolerance testing. Here, the culinary preferences of our bodies are unraveled, uncovering food sensitivities, and enabling a personalized menu for our health. Imagine a personal chef, intimately familiar with your likes and dislikes, crafting a meal plan that satisfies both your palate and your well-being.

This fusion of financial acumen and healthcare innovation promises a future where trial-and-error in medicine fades into antiquity. Adverse reactions are minimized, hospital readmissions reduced, and unnecessary costs trimmed. It’s like finding the most efficient route in a complex labyrinth – saving time, reducing confusion, and enhancing the overall journey.

Founder of Prince Laboratories, Thomas Lancie, offers a glimpse into the thinking behind this novel endeavor. “Our journey into personalized healthcare testing is a testament to our commitment to enhancing patient health outcomes while also bringing a touch of fiscal prudence to the healthcare industry,” says Lancie.

Echoing these sentiments, Thomas Lancie also adds, “Personalized medicine could be the dawn of a new era in healthcare, one where it evolves into a proactive, preventive, and patient-centered system. By unlocking the secrets of genetic information and individual dietary preferences, we give patients the keys to their health, fostering a healthier population.”

In essence, Prince Financial Group working with Prince Laboratories, John Engler,  Bryan Lantry, Alec Dierna, and Thomas Lancie, are charting a course to a future where healthcare is not just a response to illness but a customized, proactive approach to well-being.

With their compass set on pharmacogenomic and food tolerance testing, they aim to create a patient-centric healthcare system that optimizes health outcomes and pares down unnecessary costs. It’s a bold vision, a grand adventure – a testament to the power of innovation that can happen only when industry boundaries are traversed.

Advertising disclosure: We may receive compensation for some of the links in our stories. Thank you for supporting LA Weekly and our advertisers.